熱門資訊> 正文
Incyte宣布欧盟批准与Xencor合作的淋巴瘤疗法
2025-12-18 00:52
- Incyte (INCY) announced on Wednesday that the European Commission approved a drug regimen containing its Xencor (XNCR)-partnered antibody drug Minjuvi as a late-line option for certain adults with follicular lymphoma, a blood cancer.
- Accordingly, the treatment, also known as tafasitamab, will be available in the EU with other lymphoma drugs, lenalidomide and rituximab, for adults with relapsed or refractory FL who have undergone at least one line of systemic therapy.
- The approval marks the second indication for Minjuvi in the region after the EC granted conditional approval for the drug in combination with lenalidomide for certain adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
- Incyte (INCY) markets Minjuvi under an exclusive global license agreement with Xencor (XNCR), whose XmAb drug technology was used in the development of the product.
More on Incyte, Xencor
- Tracking Baker Brothers Portfolio - Q3 2025 Update
- Incyte Corporation (INCY) Presents at The 67th American Society of Hematology (ASH) Annual Meeting - Slideshow
- Incyte Corporation (INCY) Discusses mutCALR Data and Therapeutic Advances in Myeloproliferative Neoplasms at ASH - Slideshow
- FDA fast-tracks Incyte drug for rare blood cancer
- LLY joins $1T club but doesn't feature in SA's top 10 large-cap healthcare stocks
推薦文章
谷歌年初在人工智能競賽中落后，卻在2025年末登頂行業榜首
華盛早報 | 美聯儲主席熱門人選哈塞特：降息節奏仍需加速！英偉達稱春節前向中國交付H200芯片；中芯國際對部分產能漲價10%
12月24日外盤頭條：美國消費者信心連續第五個月下滑 金銀連續兩日刷新歷史新高 特朗普提美聯儲主席必要條件
美聯儲主席候選人哈塞特：美國在降息方面已嚴重滯后
美股機會日報 | 黃金再創新高！現貨黃金逼近4500美元關口；甲骨文CEO埃里森為派拉蒙提供鉅額資金擔保
資金覆盤 | 北水淨買入港股6.11億港元，加倉阿里超13億港元，賣出騰訊超10億港元
首日最高狂飆337%，港股IPO「AI含量」拉滿！壁仞、智譜、MiniMAX密集衝刺，AI上市潮已至？
年終盤點 | 流動性翻倍！1.4萬億北水買爆港股，2025年哪些公司獲重點掃貨？
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
